← Back to Search

Radiopharmaceutical

FAPI PET for Lung Fibrosis (FAPI ILD Trial)

Phase < 1
Recruiting
Led By Jeremie Calais, MD
Research Sponsored by University of California, Los Angeles
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 2 years
Awards & highlights

FAPI ILD Trial Summary

This trial is looking at how well a new imaging agent called 68-GaFAPi works in people with interstitial lung disease. The study will follow 30 patients and look at where and how much the agent accumulates in normal and diseased lung tissue.

Eligible Conditions
  • Interstitial Lung Disease
  • Extrinsic Allergic Alveolitis
  • Pneumoconiosis
  • Pulmonary Fibrosis
  • Interstitial Pneumonias
  • Pneumonitis
  • Radiation Pneumonitis

FAPI ILD Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 2 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 2 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
To define and document the biodistribution of gallium Ga 68 FAPi-46 (68Ga-FAPi-46) in patients with Interstitial Lung Disease
Secondary outcome measures
68Ga-FAPi-46 accumulation
68Ga-FAPi-46 and disease progression
68Ga-FAPi-46 biodistribution

FAPI ILD Trial Design

1Treatment groups
Experimental Treatment
Group I: 68Ga-FAPi-46Experimental Treatment4 Interventions
Patients receive 68Ga-FAPi-46 IV and undergo PET/CT scan over 20-50 minutes
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
High Resolution Computed Tomography
2021
N/A
~40
Computed Tomography
2017
Completed Phase 2
~2720
Positron Emission Tomography
2008
Completed Phase 2
~2240

Find a Location

Who is running the clinical trial?

University of California, Los AngelesLead Sponsor
1,528 Previous Clinical Trials
10,276,821 Total Patients Enrolled
Jeremie Calais, MDPrincipal InvestigatorClinical Research Director, Ahmanson Translational Theranostics
5 Previous Clinical Trials
152 Total Patients Enrolled

Media Library

68Ga-FAPi-46 (Radiopharmaceutical) Clinical Trial Eligibility Overview. Trial Name: NCT05365802 — Phase < 1
Interstitial Lung Disease Research Study Groups: 68Ga-FAPi-46
Interstitial Lung Disease Clinical Trial 2023: 68Ga-FAPi-46 Highlights & Side Effects. Trial Name: NCT05365802 — Phase < 1
68Ga-FAPi-46 (Radiopharmaceutical) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05365802 — Phase < 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the current enrollment capacity for this research project?

"Affirmative. The clinicaltrial.gov listing for this experiment confirms that it is presently taking on participants, having been initially posted on November 16th 2021 and most recently updated on May 6th 2022. 30 individuals need to be recruited from a single site."

Answered by AI

Are there enrolment opportunities for this medical experimentation?

"Affirmative, the information on clinicaltrials.gov attests to this experiment's active recruitment phase. The investigation was initially posted on November 16th 2021 and underwent its last update May 6th 2022 with a target of 30 participants from 1 medical centre."

Answered by AI
Recent research and studies
clinicaltrials.govStudy
FAPI PET for Lung Fibrosis
Jeremie Calais 2021. "FAPI PET for Lung Fibrosis". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05365802.
~9 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top